Associated Papers
Plasma thrombin-activatable fibrinolysis inhibitor and the 1040C/T polymorphism are risk factors for diabetic kidney disease in Chinese patients with type 2 diabetes.
Huang Q et al.
Peerj, 2023
Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
Fawzy MS et al.
Meta Gene, 2015
TAFI gene polymorphisms in patients with cerebral venous thrombosis.
Tokgoz S et al.
Acta Neurologica Belgica, 2013
Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
Fernandez-Cadenas I et al.
Journal of Thrombosis and Haemostasis : Jth, 2007
A new functional assay of thrombin activatable fibrinolysis inhibitor.
Guimarães AH et al.
Journal of Thrombosis and Haemostasis : Jth, 2005
Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E et al.
British Journal of Haematology, 2003
Select a paper to view details